{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+on+Day+22", "query": { "intervention": "Placebo on Day 22" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 166, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+on+Day+22&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T10:21:46.103Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06901531", "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Folinic acid (leucovorin or local equivalent)", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2025-05-22", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06901531" }, { "nct_id": "NCT04117607", "title": "Safety and Pharmacokinetics of Rezafungin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fungal Infection" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Rezafungin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 14, "start_date": "2019-12-04", "completion_date": "2020-05-11", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04117607" }, { "nct_id": "NCT01998958", "title": "A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Treatment Resistant Depressive Disorder" ], "interventions": [ { "name": "Esketamine 14 mg", "type": "DRUG" }, { "name": "Esketamine 28 mg", "type": "DRUG" }, { "name": "Esketamine 56 mg", "type": "DRUG" }, { "name": "Esketamine 84 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "20 Years to 64 Years" }, "enrollment_count": 108, "start_date": "2014-01-27", "completion_date": "2015-09-25", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Garden Grove", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998958" }, { "nct_id": "NCT02043587", "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphocytic Leukemia", "Adult Lymphoblastic Lymphoma" ], "interventions": [ { "name": "DNR", "type": "DRUG" }, { "name": "VCR", "type": "DRUG" }, { "name": "PEG-asp", "type": "DRUG" }, { "name": "CTX", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Liposomal AraC", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "LCV", "type": "DRUG" }, { "name": "AraC", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 31, "start_date": "2014-01", "completion_date": "2022-04-14", "has_results": false, "last_update_posted_date": "2022-05-02", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043587" }, { "nct_id": "NCT01040845", "title": "A Pharmacokinetic Study of Colchicine With an Oral Contraceptive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "Norethindrone/Ethinyl Estradiol", "type": "DRUG" }, { "name": "Colchicine", "type": "DRUG" }, { "name": "Placebo (for Colchicine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mutual Pharmaceutical Company, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 30, "start_date": "2007-08", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2010-01-05", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01040845" }, { "nct_id": "NCT02748694", "title": "Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Schizophrenia" ], "interventions": [ { "name": "TAK-041", "type": "DRUG" }, { "name": "TAK-041 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 114, "start_date": "2016-05-09", "completion_date": "2019-09-22", "has_results": true, "last_update_posted_date": "2021-03-19", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02748694" }, { "nct_id": "NCT02493868", "title": "A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 719, "start_date": "2015-10-01", "completion_date": "2018-02-16", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02493868" }, { "nct_id": "NCT01862991", "title": "Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Legally Induced Abortion Without Mention of Complication" ], "interventions": [ { "name": "Hygroscopic cervical dilators", "type": "OTHER" }, { "name": "Misoprostol", "type": "DRUG" }, { "name": "Intra-amniotic digoxin", "type": "DRUG" }, { "name": "Mifepristone", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2013-07", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2024-02-14", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 2, "location_summary": "San Jose, California • Stanford, California", "locations": [ { "city": "San Jose", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01862991" }, { "nct_id": "NCT02504008", "title": "CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complex Regional Pain Syndrome", "Reflex Sympathetic Dystrophy" ], "interventions": [ { "name": "AXS-02 (oral zoledronate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Axsome Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2015-07", "completion_date": "2019-01", "has_results": false, "last_update_posted_date": "2018-03-23", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 29, "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Encinitas, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02504008" }, { "nct_id": "NCT04078022", "title": "Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Shigella" ], "interventions": [ { "name": "SF2a-TT15 Shigella Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "S. flexneri 2a strain 2457T Challenge Agent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 58, "start_date": "2020-03-02", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2024-05-20", "last_synced_at": "2026-09-23T10:21:46.103Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04078022" } ] }